Assignee
EXELIXIS INC
US·123 granted patents·143 pending applications·1,935 citations·filing 1998–2025
Top patents by PatentIndex Score
266 records- 0198US10039757B2C-Met modulator pharmaceutical compositionsEXELIXIS INC·Filed 2017·Granted Aug 7, 2018·33 cites·19 claims
- 0298US10034873B2C-met modulator pharmaceutical compositionsEXELIXIS INC·Filed 2017·Granted Jul 31, 2018·33 cites·19 claims
- 0398US7579473B2c-Met modulators and methods of useEXELIXIS INC·Filed 2009·Granted Aug 25, 2009·95 cites·7 claims
- 0498US7265131B2Isoquinolinone derivatives and their use as therapeutic agentsEXELIXIS INC·Filed 2003·Granted Sep 4, 2007·145 cites·27 claims
- 0597US11731941B2Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of useEXELIXIS INC·Filed 2022·Granted Aug 22, 2023·8 cites·18 claims
- 0697US11098015B2Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancerEXELIXIS INC·Filed 2021·Granted Aug 24, 2021·9 cites·3 claims
- 0797US11091440B2Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancerEXELIXIS INC·Filed 2021·Granted Aug 17, 2021·8 cites·3 claims
- 0897US11091439B2Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancerEXELIXIS INC·Filed 2020·Granted Aug 17, 2021·8 cites·5 claims
- 0996US11298349B2Processes for preparing quinoline compounds and pharmaceutical compositions containing such compoundsEXELIXIS INC·Filed 2021·Granted Apr 12, 2022·4 cites·3 claims
- 1096US10548888B2C-Met modulator pharmaceutical compositionsEXELIXIS INC·Filed 2018·Granted Feb 4, 2020·9 cites·19 claims
- 1196US10543206B2Processes for preparing quinoline compounds and pharmaceutical compositions containing such compoundsEXELIXIS INC·Filed 2018·Granted Jan 28, 2020·9 cites·20 claims
- 1296US10123999B2Processes for preparing quinoline compounds and pharmaceutical compositions containing such compoundsEXELIXIS INC·Filed 2016·Granted Nov 13, 2018·9 cites·11 claims
- 1396US7989622B2Phosphatidylinositol 3-kinase inhibitors and methods of their useEXELIXIS INC·Filed 2006·Granted Aug 2, 2011·64 cites·7 claims
- 1496US7803839B2Azetidines as MEK inhibitors for the treatment of proliferative diseasesEXELIXIS INC·Filed 2006·Granted Sep 28, 2010·46 cites·68 claims
- 1595US11724986B2Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of useEXELIXIS INC·Filed 2020·Granted Aug 15, 2023·6 cites·4 claims
- 1695US11124482B2C-met modulators and methods of useEXELIXIS INC·Filed 2017·Granted Sep 21, 2021·6 cites·11 claims
- 1795US9809549B2Malate salt of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancerEXELIXIS INC·Filed 2014·Granted Nov 7, 2017·30 cites·5 claims
- 1895US7999006B2Methods of using MEK inhibitorsEXELIXIS INC·Filed 2007·Granted Aug 16, 2011·51 cites·27 claims
- 1995US7977345B2c-MET modulators and method of useEXELIXIS INC·Filed 2005·Granted Jul 12, 2011·48 cites·3 claims
- 2095US6515109B1Human ECT2 polypeptideEXELIXIS INC·Filed 2001·Granted Feb 4, 2003·179 cites·1 claims
- 2195US6489127B1Methods for identifying anti-cancer drug targetsEXELIXIS INC·Filed 2000·Granted Dec 3, 2002·194 cites·3 claims
- 2294US11433064B2Methods of using c-Met modulatorsEXELIXIS INC·Filed 2020·Granted Sep 6, 2022·6 cites·4 claims
- 2394US10851061B2Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of useEXELIXIS INC·Filed 2019·Granted Dec 1, 2020·8 cites·8 claims
- 2494US10159666B2Dosing of cabozantinib formulationsEXELIXIS INC·Filed 2015·Granted Dec 25, 2018·21 cites·8 claims
- 2594US7915250B2Azetidines as MEK inhibitors for the treatment of proliferative diseasesEXELIXIS INC·Filed 2010·Granted Mar 29, 2011·22 cites·26 claims
- 2694US7704995B2Protein kinase modulators and methods of useEXELIXIS INC·Filed 2003·Granted Apr 27, 2010·64 cites·35 claims
- 2794US6703491B1Drosophila sequencesEXELIXIS INC·Filed 1999·Granted Mar 9, 2004·123 cites·18 claims
- 2894US6511824B1Nucleic acids and polypeptides of invertebrate TWIK channels and methods of useEXELIXIS INC·Filed 1999·Granted Jan 28, 2003·195 cites·5 claims
- 2993US10736886B2Methods of using c-Met modulatorsEXELIXIS INC·Filed 2019·Granted Aug 11, 2020·11 cites·6 claims
- 3093US9969692B2Process for preparing quinoline derivativesEXELIXIS INC·Filed 2016·Granted May 15, 2018·21 cites·21 claims
- 3193US9861624B2Method of treating cancerEXELIXIS INC·Filed 2013·Granted Jan 9, 2018·24 cites·3 claims
- 3292US12275706B2Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancerEXELIXIS INC·Filed 2024·Granted Apr 15, 2025·0 cites·6 claims
- 3392US11760726B2Crystalline solid forms of N-{4-[(6,7-Dimethoxyquinolin-4-yl)oxy]phenyl} -n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of useEXELIXIS INC·Filed 2021·Granted Sep 19, 2023·2 cites·11 claims
- 3492US11279675B2Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of useEXELIXIS INC·Filed 2018·Granted Mar 22, 2022·10 cites·16 claims
- 3592US11123338B2C-met modulator pharmaceutical compositionsEXELIXIS INC·Filed 2019·Granted Sep 21, 2021·2 cites·27 claims
- 3692US10501418B2Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of useEXELIXIS INC·Filed 2015·Granted Dec 10, 2019·12 cites·11 claims
- 3792US10273211B2Metabolites of N-{4-([6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamideEXELIXIS INC·Filed 2014·Granted Apr 30, 2019·17 cites·2 claims
- 3892US10166225B2Method for treating osteoporosisEXELIXIS INC·Filed 2012·Granted Jan 1, 2019·23 cites·9 claims
- 3992US9365516B2Process for preparing quinoline derivativesEXELIXIS INC·Filed 2012·Granted Jun 14, 2016·27 cites·28 claims
- 4092US7485634B2Azepinoindole and pyridoindole derivatives as pharmaceutical agentsEXELIXIS INC·Filed 2003·Granted Feb 3, 2009·49 cites·100 claims
- 4191US12016854B2Liquid dosage forms to treat cancerEXELIXIS INC·Filed 2022·Granted Jun 25, 2024·1 cites·7 claims
- 4291US11065240B2Drug combinations to treat multiple myelomaEXELIXIS INC·Filed 2015·Granted Jul 20, 2021·6 cites·4 claims
- 4391US8372851B2Pyrazolo pyrimidines as casein kinase II (CK2) modulatorsEXELIXIS INC·Filed 2006·Granted Feb 12, 2013·20 cites·12 claims
- 4491US8362002B2Azetidines as MEK inhibitors for the treatment of proliferative diseasesEXELIXIS INC·Filed 2011·Granted Jan 29, 2013·12 cites·63 claims
- 4591US2025367186A1C-Met Modulator Pharmaceutical CompositionsEXELIXIS INC·Filed 2025·Application pending·0 cites
- 4690US12128039B2Processes for preparing quinoline compounds and pharmaceutical compositions containing such compoundsEXELIXIS INC·Filed 2024·Granted Oct 29, 2024·0 cites·22 claims
- 4790US11141413B2Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioateEXELIXIS INC·Filed 2017·Granted Oct 12, 2021·8 cites·21 claims
- 4890US2025017916A1Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such CompoundsEXELIXIS INC·Filed 2024·Application pending·0 cites
- 4989US2025100966A1Mek inhibitors and methods of their useEXELIXIS INC·Filed 2024·Application pending·0 cites
- 5089US2024156804A1C-Met Modulator Pharmaceutical CompositionsEXELIXIS INC·Filed 2023·Application pending·0 cites
Showing the top 50 of 266 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →